MAI Capital Management’s Solid Biosciences SLDB Stock Holding History

MAI Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-123	Closed	-$886	–	4311
2026 Q1	$886	Hold	123	–	–	﹤0.01%	4224
2025 Q4	$694	Hold	123	–	–	﹤0.01%	3741
2025 Q3	$759	Hold	123	–	–	﹤0.01%	3543
2025 Q2	$600	Hold	123	–	–	﹤0.01%	3736
2025 Q1	$456	Buy	+123	New	+$527	﹤0.01%	3242

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MAI Capital Management's SLDB Position: Q2 2026 in Review

MAI Capital Management sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 123 shares — an estimated $886 sold.

MAI Capital Management first reported a position in SLDB in Q1 2025 and held it in 5 quarters. The position peaked at $886 in Q1 2026. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

MAI Capital Management reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 123 Solid Biosciences shares in Q2 2026, an estimated $886.
MAI Capital Management first reported a position in Solid Biosciences in Q1 2025 and held it in 5 quarters.
MAI Capital Management's Solid Biosciences position peaked at $886 in Q1 2026.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.